Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Phase 1b/2 Study to Assess the Safety, Tolerability and Efficacy of BGB-290 in Combination With Radiation Therapy (RT) and/or Temozolomide (TMZ) in Subjects With First-line or Recurrent/Refractory Glioblastoma

NCT03150862 is registered in ClinicalTrials.gov with BeiGene USA, Inc. as lead sponsor.

NCT NCT03150862
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT03150862 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Phase 1b/2 Study to Assess the Safety, Tolerability and Efficacy of BGB-290 in Combination With Radiation Therapy (RT) and/or Temozolomide (TMZ) in Subjects With First-line or Recurrent/Refractory Glioblastoma
Lead sponsor
BeiGene USA, Inc.
Phase
Phase 1/2
Overall status
Completed
Start date
July 24, 2017
Completion date
March 17, 2021
Enrollment
116 (actual)
Sites
22

Conditions

As the registry lists them; a condition with its own page is linked.

brain and central nervous system tumors